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Abstract
Background: ADHD is currently defined as a cognitive/behavioral developmental disorder where all clinical criteria
are behavioral. Overactivity, impulsiveness, and inattentiveness are presently regarded as the main clinical
symptoms. There is no biological marker, but there is considerable evidence to suggest that ADHD behavior is
associated with poor dopaminergic and noradrenergic modulation of neuronal circuits that involve the frontal
lobes. The best validated animal model of ADHD, the Spontaneously Hypertensive Rat (SHR), shows pronounced
overactivity, impulsiveness, and deficient sustained attention. The primary objective of the present research was to
investigate behavioral effects of a range of doses of chronic l-amphetamine on ADHD-like symptoms in the SHR.
Methods: The present study tested the behavioral effects of 0.75 and 2.2 mg l-amphetamine base/kg i.p. in male
SHRs and their controls, the Wistar Kyoto rat (WKY). ADHD-like behavior was tested with a visual discrimination task
measuring overactivity, impulsiveness and inattentiveness.
Results: The striking impulsiveness, overactivity, and poorer sustained attention seen during baseline conditions in
the SHR were improved by chronic treatment with l-amphetamine. The dose-response curves were, however,
different for the different behaviors. Most significantly, the 0.75 mg/kg dose of l-amphetamine improved sustained
attention without reducing overactivity and impulsiveness. The 2.2 mg/kg dose improved sustained attention as
well as reduced SHR overactivity and impulsiveness.
Discussion: The effects of l-amphetamine to reduce the behavioral symptoms of ADHD in the SHR were
maintained over the 14 days of daily dosing with no evidence of tolerance developing.
Background
Attention-deficit/hyperactivity disorder (ADHD) is cur-
rently defined as a cognitive developmental disorder
where all clinical criteria are behavioral [1]. Overactivity,
impulsiveness, and inattentiveness are presently
regarded as the main clinical symptoms.
There have been many attempts to explain the origins
of ADHD symptoms. A dual-process theory [2-5] sug-
gests that less efficient reinforcement processes and defi-
cient extinction of previously reinforced behavior may
explain behavioral changes often described as response
disinhibition [6] or poor executive functioning [7].
ADHD is highly heritable and the genetic and neuro-
biological causes are likely to reside in brain catechola-
mines (for a review see [4]). Most likely, ADHD
symptoms are associated with reduced post-synaptic
efficacy of dopaminergic and noradrenergic modulation
of neuronal circuits that involve the frontal lobes [8,9].
Imaging of striatal neuronal networks indicates reduced
dopamine efficacy in ADHD [10]. Further, noradrenergic
systems are involved in attention processes and prime
prefrontal areas for response to sensory stimuli [11]. It
is therefore not surprising that amphetamines and other
catecholamine agonists have been the drugs of choice in
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mine agonists improve behavior, long-term academic
performance is not improved to the same extent [14-18].
The spontaneously hypertensive rat (SHR) is the best
validated animal model of ADHD. These rats show
hyperactivity, impulsiveness and deficits in sustained
attention [9,19-22]. The control strain is usually the
Wistar Kyoto Rat (WKY) as this rat is the progenitor
strain and its behavior is closely similar to that of other
strains when tested in well-controlled operant tasks [20].
Drugs used in the pharmacological treatment of ADHD,
usually catecholamine agonists have been shown to
reduce ADHD-like behavior in this model [19,22-25].
Results from animal studies indicate that higher doses
of amphetamines are required for reducing SHR overac-
tivity and impulsiveness than those required for improv-
ing SHR sustained attention which, in children, is
essential for long-term academic performance [22].
Although d-amphetamine improves SHR overactivity
and impulsiveness as well as sustained attention, the
behavioral effects of l-amphetamine were relatively more
specific for improving sustained attention than for the
other two symptoms [22].
The primary objective of the present study was to test
the effects of chronic administration of 0.75 and 2.2 mg
l-amphetamine base/kg i.p. to male SHRs and their con-
trols, the Wistar Kyoto rat (WKY), in a visual discrimi-
nation task measuring overactivity, impulsiveness and
inattentiveness. Lower doses were used than in a pre-
vious single-dose study [22].
Methods
Subjects
A total number of 91 male rats, 47 SHR and 44 WKY,
participated in this study. At the start of testing follow-
ing 3 days acclimatization, the rats were 5 wk old and
experimentally naïve. Young rats were required, as
ADHD primarily is a child and adolescent disorder. Due
to health status requirements, half of the SHRs were
obtained from Charles River Germany (SHR/NCrl), the
other half from Charles River Italy (SHR/NCrl). The
WKYs were from Charles River Germany (WKY/NCrl).
At the University of Oslo, the rats were housed indivi-
dually in 41 × 25 × 25 (height) cm transparent cages
and had free access to food (RM3 (E) from Special Diet
Services, Witham, Essex CM8 3AD, UK). The rats had
access to water at all times before the habituation ses-
sion. Starting following completion of the habituation
session, the rats were deprived of water for 21 hr a day;
this is a moderate, but sufficient deprivation for motivat-
ing the animal. The temperature in the housing area was
~22°C. The light was on from 0700 to 1900 hours. The
behavioral training took place between 1000 and 1530
hours seven days a week. The experiments were
approved by the Norwegian Animal Research Authority
(NARA), and were conducted in accordance with the
laws and regulations controlling experimental proce-
dures in live animals in Norway and the European
Union’s Directive 86/609/EEC.
Behavioral apparatus
Sixteen Campden Instruments operant chambers were
used in the study. The animal’s working space in eight
of the chambers was 25 × 25 × 30 (height) cm and 25 ×
25 × 20 (height) cm in the other eight chambers. A fan
producing a low masking noise and the 2.8-W house
light were on during the entire experimental session.
During training sessions, either no, one or both
retractable levers were used (below). A 2.8-W cue light
was located above each lever. The rats’ response con-
sisted of pressing one of the levers with a dead weight
of at least 3 g to activate a micro-switch. The reinforcers
(0.01 ml tap water) were delivered by a liquid dipper
located in a small recessed cubicle with a 2.8-W cue
light that lit up when a reinforcer was presented. A 7 ×
5 cm transparent plastic lid separated the cubicle from
the rat’s working space. The rat could easily open the
lid with a light push with the nose or paw. Each cham-
ber was ventilated and placed in a sound-resistant outer
housing. A computer and an online system (SPIDER,
Paul Fray, Ltd., UK) recorded the behavior and sched-
uled reinforcers (drops of water).
Before the initiation of the study, the rats were
assigned a chamber (1 through 16) and time of testing
(10, 12 or 14 o’clock) in a randomized and balanced
way. The rat was returned to its living cage after each
session and immediately given free access to water for
60 min.
Response acquisition
The training period started with a single 30-min habi-
tuation session. During the habituation session, the lid
between the working space and the reinforcement cubi-
cle was kept open. The house light was on, but no lever
was present, no cue light above any lever was lit and
water was not delivered.
The habituation session was followed by two dipper
training sessions, lasting 30 and 15 min, respectively.
The lid was taped open, no levers were present, and the
house light was on, but the cue lights above the levers
were not lit. The computer delivered water on the aver-
age every 10 s independent of the rat’s behavior (a vari-
able-time schedule). Each water delivery was
accompanied by the turning on of the cue light in the
small recessed cubicle.
In the next two 30-min sessions, the rat was trained to
open the lid to gain access to the water. The lid was not
taped open, no levers were present and the lights above
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Each lid opening was followed by a presentation of a
single drop of water. The cue light in the recessed cubi-
cle was turned on when water was present.
During the subsequent three to four sessions (depend-
ing on performance), lever responding was shaped by
the method of successive approximations [26]. During
the initial sessions, the rats learned to press the left
lever in order to receive a reinforcer immediately follow-
ing every press. The cue light above the left lever was
now lit the entire session. The right lever was retracted
into the wall. On the final session, the right lever was
activated and the left lever retracted. During this session
the light above the right lever was lit the entire session
and the light above the left lever was off. The house
light was on during both sessions. Following this shap-
ing procedure, the animal had acquired the appropriate
lever-pressing behavior.
From now on, both levers were present. The light
above the levers shifted randomly. The light stayed lit
above a lever for as long as it was the correct lever. This
was the discriminative stimulus showing the rat which
lever it had to press in order to receive a reinforcer. A
concurrent extinction schedule was present on the
wrong lever. There was never any light above the extinc-
tion lever. Thus, the present task was a simultaneous
visual discrimination task. The seven sessions lasted for
30 min and the reinforcers were delivered following
every correct lever press. Whenever an interval had
elapsed, the reinforcer was delivered immediately follow-
ing the first correct response.
Final schedule
The simultaneous visual discrimination task was used
for testing effects of the drugs. An unpredictable 180-s
random-interval schedule was in effect for 90 min on
the correct lever (signaled by a constantly lit cue light
above this lever) from session 18 on until the study was
finished at session 61. Inter-reinforcer times ranged
from 6 to 719 s in a randomized fashion with a skewed
distribution modeled after the “Harvard golden tape”
[27]. There was neither any external stimulus signaling
that a reinforcer was programmed, nor any external sti-
mulus signaling the time since the last response. A con-
current extinction schedule (never associated with any
cue light) was present on the wrong lever. The house
light was lit the entire session.
Behavioral measures
Each session was divided into five 18-min segments
(parts) in order to monitor intra-session changes in the
behavior. For each segment, total number of presses on
the correct and incorrect lever as well as number of
reinforcers delivered were recorded. Time between
consecutive correct responses (inter-response time, IRT)
was also recorded.
The total number of lever presses is an expression of
the general activity level and therefore a measure of
degree of activity. The percent choice of the correct lever
when the reinforcers are delivered infrequently is a mea-
sure of sustained attention [22]. The number of
responses with short IRTs (< 0.67 s) is used as a measure
of degree of impulsiveness (cannot hold back a response
even when one knows it is an unnecessary one).
Drug administration
The animals were randomly assigned to three treatment
groups: 0.75 or 2.2 mg/kg l-amphetamine sulphate or
vehicle (physiological saline). Each rat was injected
intraperitoneally at a dose volume of 1 ml/kg body
weight of the animal ~30 min before testing. The daily
administration of the drug started at session 45 when
the behavior had stabilized and ended at session 58
except for the saline groups that received 2.2 mg/kg
l-amphetamine ~30 min before sessions 59-61 in order
to check that the drug response of these groups was the
same as their counterparts.
Drugs
l-Amphetamine sulphate (Lot FB-101-57) was supplied
from Boeringer-Ingelheim US. Doses were calculated as
the weight of base using a conversion factor of 1.360 mg
sulphate salt as equivalent to 1.000 mg base. Doses were
based on previously published data [22]. Dosing solu-
tions were prepared in physiological saline. The drug
solutions were prepared each day of dosing.
Data management and statistical procedures
The mean behavior was regarded as the drug response.
The data were processed by univariate and multivariate
analyses of variance (ANOVAs and MANOVAs, respec-
tively) with the Statistica 7.1 program [28]. Strain and
dose were between-subject variables coded as subgroups.
One control rat fell ill early in the study and had to be
sacrificed. Post-hoc comparisons following MANOVAs
were performed by the Newman-Keuls test.
Results
General
Compared to WKY controls, SHRs showed poorer sus-
tained attention (Figure 1), pronounced overactivity
(Figure 2), and impulsiveness (Figure 3) (see Additional
files 1 and 2). There were clear dose-response curves to
l-amphetamine in the SHR, but the dose-response
curves were different for the different behaviors. The
0.75 mg/kg dose improved SHR sustained attention,
without reducing overactivity and impulsiveness. The
2.2 mg/kg dose improved attention, overactivity and
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Page 3 of 10Figure 1 Effects of l-amphetamine on sustained attention, choice of the correct lever in percent of all lever presses, by SHR and WKY
controls. Means ± SEM. Sessions 31 through 44 served as baseline sessions. Treatment was given at sessions 45 through 58. Sessions 59
through 61 were used for studying post-treatment effects, except for the groups that received vehicle (saline, 0 mg/kg) during treatment
sessions 45-58. These groups received 2.2 mg/kg l-amphetamine to check for typical responsiveness to the drug for SHR and WKY.
Figure 2 Effects of l-amphetamine on total number of lever presses (correct plus incorrect) by SHR and WKY controls. Means ± SEM.
Sessions 31 through 44 served as baseline sessions. Treatment was given at sessions 45 through 58. Sessions 59 through 61 were used for
studying post-treatment effects, except for the groups that received vehicle (saline, 0 mg/kg) during treatment sessions 45-58. These groups
received 2.2 mg/kg l-amphetamine to check for typical responsiveness to the drug for SHR and WKY.
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maintained over the 14 days of daily dosing. The effects
were only present during sessions with active drug. The
drug had little effect on WKY behavior.
Acquisition
A si st h ec a s ei nc h i l d r e nw i t hA D H D[ 2 9 , 3 0 ] ,t h e
symptoms in the SHR developed with time, but differ-
ently for the different behaviors [21]. The final schedule
was installed on session 18. Sustained attention
improved in the WKY controls and stabilized at about
session 30 (Figure 1). A pronounced overactivity was
seen in SHRs from session 18 onwards (Figure 2). SHR
impulsiveness, responding within 0.67 s since the pre-
vious lever press although such a lever press was rarely
reinforced, continued to increase in the SHR throughout
the entire study [21]. This measure was accompanied by
increased variability over days during the course of the
study, something that is typical in ADHD [31-33].
Impulsiveness was subjected to a log10-transformation
in order to obtain the more equal variances required by
the ANOVAs (Figure 3). For all three behaviors, the
three SHR subgroups were closely similar before the
start of the injection program. So were the three WKY
subgroups.
Sustained attention
Without medication, SHRs showed poorer sustained
attention than WKY controls. The three SHR subgroups
were closely similar before the start of the injection pro-
gram, as were the three WKY subgroups (Figure 1).
L-amphetamine produced a dose-related improvement
in sustained attention in the SHR, but not in the WKY.
This improvement was maintained throughout the 14
day dosing period (sessions 45-58) (Figure 1). A similar
effect of the 2.2 mg/kg dose was seen in the SHR sub-
group which received vehicle (saline, 0 mg/kg) during
sessions 45 through 58 and then received the drug dur-
ing sessions 59 through 61 (Figures 1 and 4). The drug
effect did not transfer to sessions following the cessation
of drug administration. For the WKYs, 0.75 mg/kg
l-amphetamine did not alter attentional behavior, but
the 2.2 mg/kg dose produced a slight deterioration in
behavior after dosing was terminated (Figure 4).
Acute and chronic effects of l-amphetamine
The ANOVA comparing effects during pre-drug treat-
ment (days 31 to 44) with effects during drug treatment
(days 45 to 58) showed a statistically significant main
effect of subgroup (F(3,87) = 14.62, p < 0.001). The
MANOVA showed a main effect of treatment (F(1,87) =
52.21, p < 0.001), a main effect of segment of session
Figure 3 Effects of l-amphetamine on impulsiveness, responding within 0.67 s following the previous lever press, of SHR and WKY
controls following log10 transformation. Means ± SEM. Sessions 31 through 44 served as baseline sessions. Treatment was given at sessions
45 through 58. Sessions 59 through 61 were used for studying post-treatment effects, except for the groups that received vehicle (saline, 0 mg/
kg) during treatment sessions 45-58. These groups received 2.2 mg/kg l-amphetamine to check for typical responsiveness to the drug for SHR
and WKY.
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Page 5 of 10(F(4,84) = 12.98, p < 0.001), a 2-way subgroup × treat-
ment interaction (F(3,87) = 6.63, p < 0.001), but no 3-
way subgroup × treatment × segment interaction (F
(12,223) = 1.36, p > 0.1). The acute drug effects in the
subgroups receiving 2.2 mg/kg during sessions 59
through 61 were compared to their behavior during ses-
sions 45 through 58, when they received saline, and
combined with the other animals of the same strain
receiving 2.2 mg/kg during sessions 45 through 58.
Thus, the drug had a larger effect in SHR than in WKY
controls (Figures 1 and 4).
In order to check for the stability of the drug effects
over the 14 days of daily dosing, the 14 treatment ses-
sions were divided into two halves, the initial seven ses-
sions and the final seven sessions. The MANOVA of the
sustained attention behavior of the subgroups receiving
an active dose showed no statistically significant
development from the 1
st to the 2
nd half of the test per-
iod. The subgroup × half test period interaction was: F
(3,58) = 0.96, p > 0.4).
Overactivity
Without medication, SHRs showed a substantially
higher activity than WKY controls. The three SHR sub-
groups were closely similar before the start of the injec-
tion program, as were the three WKY subgroups
(Figures 2 and 5). L-amphetamine, 2.2 mg/kg, reduced
hyperactivity in the SHR, whilst having no effect on
activity in the WKY. The improvement in the SHR was
maintained throughout the 14-day dosing period (Figure
2). A similar effect of the 2.2 mg/kg dose was seen in
the SHR subgroup which received vehicle (saline, 0 mg/
kg) during sessions 45 through 58 and then received the
drug during sessions 59 through 61 (Figures 2 and 5).
Figure 4 This figure shows the mean within-session effects of l-amphetamine on sustained attention. Left panel: Sessions 31 through
44, baseline sessions. The three SHR subgroups are closely similar, so are the three WKY subgroups, prior to the injection program. Middle
panel: Sessions 45 through 58, treatment sessions. Both doses improve SHR behavior. Right panel: Sessions 59 through 61, post-treatment
sessions. The SHR subgroups return to pre-drug levels. The 2.2 mg/kg WKY subgroup apparently got worse following drug exposure. The WKY
performance appears unaltered from pre- to post-treatment days. The groups that had received saline during sessions 45 through 58, now
received 2.2 mg/kg.
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sions following the cessation of drug administration.
The 0.75 mg/kg dose had no effect. There was no
apparent effect of the drug in the WKY controls.
Acute and chronic effects of l-amphetamine
The ANOVA showed a statistically significant main
effect of subgroup (F(3,87) = 34.10, p < 0.001). The
MANOVA showed a main effect of treatment (F(1,87) =
52.81, p < 0.001), a main effect of segment of session (F
(4,84) = 62.23, p < 0.001), a 2-way subgroup × treatment
interaction (F(3,87) = 34.20, p < 0.001), a 2-way sub-
group × segment of session interaction (F(12,223) =
6.35, p < 0.001), and a 3-way subgroup × treatment ×
segment interaction (F(12,223) = 5.91, p < 0.001). The
acute drug effects in the subgroups receiving 2.2 mg/kg
during sessions 59 through 61 were compared to their
behavior during sessions 45 through 58, when they
received saline, and combined with the other animals of
the same strain receiving 2.2 mg/kg during sessions 45
through 58. Thus, the results showed that the SHR
receiving 2.2 mg/kg had a larger effect in SHR than in
WKY controls (Figures 2 and 5).
Stability of the drug effects over the 14 days of daily
dosing was checked by dividing the 14 treatment ses-
sions, into two halves, the initial seven sessions and the
final seven sessions. The MANOVA of the activity of
the subgroups receiving an active dose showed no statis-
tically significant development from the 1
st to the 2
nd
half of the test period. The subgroup × half test period
interaction was: F(3,58) = 1.70, p > 0.15.
Impulsiveness
Without medication, SHRs were substantially more
impulsive than WKY controls. The three SHR sub-
groups were closely similar before the start of the injec-
tion program, as were the three WKY subgroups
Figure 5 This figure shows the mean within-session effects of l-amphetamine on activity. Left panel: Sessions 31 through 44, baseline
sessions. The three SHR subgroups are closely similar, so are the three WKY subgroups, prior to the injection program. Middle panel: Sessions
45 through 58, treatment sessions. 2.2 mg/kg reduces SHR overactivity. Right panel: Sessions 59 through 61, post-treatment sessions. The 2.2
mg/kg SHR subgroup returns to pre-drug levels. The WKY subgroups are apparently unaffected by the drug. The subgroups that had received
saline during sessions 45 through 58, now received 2.2 mg/kg.
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impulsiveness in the SHR, whilst having no effect in the
WKY. The improvement in impulsiveness was main-
tained throughout the 14-day dosing period (Figure 3).
A similar effect of the 2.2 mg/kg dose was seen in the
SHR subgroup which received vehicle (saline, 0 mg/kg)
during sessions 45 through 58 and then received the
drug during sessions 59 through 61 (Figure 3). The 0.75
mg/kg dose had no effect in any of the subgroups. The
2.2 mg/kg drug effect was not transferred to sessions
following the cessation of drug administration.
Acute and chronic effects of l-amphetamine
The ANOVA showed a statistically significant main
effect of subgroup (F(3,87) = 10.00, p < 0.001). The
MANOVA did not show a main effect of treatment
(F(1,87) = 2.96, p > 0.08), but a main effect of segment
of session (F(4,84) = 32.31, p < 0.001), a 2-way subgroup
× treatment interaction (F(3,87) = 3.77, p < 0.02), a 2-
way subgroup × segment of session interaction
(F(12,223) = 2.73, p < 0.002), but no 3-way subgroup ×
treatment × segment interaction (F(12,223) = 0.94, p >
0.5). The acute drug effects in the subgroups receiving
2.2 mg/kg during sessions 59 through 61 were compared
to their behavior during sessions 45 through 58, when
they received saline, and combined with the other ani-
mals of the same strain receiving 2.2 mg/kg during ses-
sions 45 through 58. Thus, the results showed that the
SHR receiving 2.2 mg/kg had a larger effect in SHR
than in WKY controls (Figures 3 and 6).
Stability of the drug effects over the 14 days of daily
dosing was checked by dividing the 14 treatment ses-
sions into two halves, the initial seven sessions and the
final seven sessions. The MANOVA of the impulsive-
ness of the subgroups receiving an active dose no
Figure 6 This figure shows the mean within-session effects of l-amphetamine. Left panel: Sessions 31 through 44, baseline sessions. The
three SHR subgroups are closely similar, so are the three WKY subgroups, prior to the injection program. Middle panel: Sessions 45 through 58,
treatment sessions. The 2.2 mg/kg dose reduced SHR impulsiveness. Right panel: Sessions 59 through 61, post-treatment sessions. The 2.2 mg/
kg SHR subgroup returned to pre-drug levels. The 2.2 mg/kg WKY subgroup apparently got worse following drug exposure. The subgroups that
had received saline during sessions 45 through 58, now received 2.2 mg/kg l-amphetamine.
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st to the
2
nd half of the test period. The subgroup × half test per-
iod interaction was: F(3,58) = 1.27, p > 0.4.
Reinforcers delivered
The random-interval reinforcement schedule used was
programmed so that even large individual differences in
lever pressing would result in approximately 6 reinfor-
cers (drops of water) during each 18-min segment of
the session, even for the case of the less active group. A
major advantage of such a schedule is the fact that sys-
tematic strain differences in thirst should not be of con-
cern when interpreting the data. The results show that
both strains in general also received 6 reinforcers per
segment during active drug.
Stereotypy and severely drugged behavior
These doses of l-amphetamine did not produce stereo-
typy or severely drugged behavior in the animals.
Discussion
ADHD is currently defined as a cognitive/behavioral
developmental disorder where all clinical criteria are
behavioral. Overactivity, impulsiveness, and inattentive-
ness are presently regarded as the main clinical symp-
toms [1]. These symptoms have been operationalized in
a long series of translational research studies investigat-
ing ADHD behavior in children and animal models (e.g.
[30-35]).
ADHD is highly heritable and the genetic and neuro-
biological causes are likely to reside in reduced postsy-
naptic effects of catecholamines on glutamatergic and
GABAergic neurons [4]. These changes apparently cause
less efficient reinforcement processes and deficient
extinction of previously reinforced behavior [3-5].
Amphetamines and other dopamine agonists have
been the drugs of choice in medication of ADHD
[8,9,12-14]. The primary objectives of the present
research were to test the behavioral effects of chronic
administration of 0.75 and 2.2 mg/kg l-amphetamine in
SHRs and their controls, the Wistar Kyoto rat (WKY) in
a visual discrimination task measuring overactivity,
impulsiveness and inattentiveness.
The results showed that both doses of l-amphetamine
improved sustained attention in the SHR, but only the
2.2 mg/kg dose reduced SHR overactivity and impulsive-
ness. These effects are similar to those seen previously
after acute administration of the drug [22]. The current
study has shown that these acute effects of l-ampheta-
mine are maintained with repeated daily dosing over 14
days, with no evidence of tolerance developing. Results
from the present as well as a previous study [22] indi-
cate that higher doses of amphetamines are required for
reducing SHR overactivity and impulsiveness than those
required for improving SHR sustained attention.
In conclusion, low doses of l-amphetamine improved
sustained attention while higher doses improved sus-
tained attention as well as overactivity and impulsive-
ness in the SHR. These effects were maintained on
chronic dosing.
Additional material
Additional file 1: The video shows a normal male WKY control rat
performing the visual discrimination task.
Additional file 2: The video shows a Spontaneously Hypertensive
Rat (SHR) performing the visual discrimination task. The rat is
overactive and inattentive.
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